Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411420 | 0.94 | HCRTR1 (0.41) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14071788 | 0.94 | HCRTR1 (0.41) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL4406340 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14071838 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14071842 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14477478 | 0.87 | LRRK2 (0.41) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14477479 | 0.84 | LRRK2 (0.40) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL4409498 | 0.79 | HCRTR1 (0.42) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL14071787 | 0.79 | HCRTR1 (0.42) | HCRTR1HCRTR2FKBP1ALRRK2 | |
| SCHEMBL13594853 | 0.78 | HCRTR1 (0.42) | HCRTR1HCRTR2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653269-B2 | Process for preparation of t-butoxycarbonylamine compounds | NIPPON SODA CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | NIPPON SODA CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005981-A1 | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | BPGM, TST, BET1 | HCRTR1 4591/4885HCRTR2 4307/4885FKBP1A 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.